Search results for "Injection"

showing 10 items of 920 documents

A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.

2018

In this independent, multicenter, retrospective study, we investigated the short-term persistence to treatment with first-line self-injectable or oral disease-modifying treatments (DMTs) in patients with relapsing–remitting multiple sclerosis. Data of patients regularly attending 21 Italian MS Centres who started a self-injectable or an oral DMT in 2015 were collected to: (1) estimate the proportion of patients discontinuing the treatment; (3) explore reasons for discontinuation; (3) identify baseline predictors of treatment discontinuation over a follow-up period of 12 months. We analyzed data of 1832 consecutive patients (1289 women, 543 men); 374 (20.4%) of them discontinued the prescrib…

MaleInjectionTime FactorsPatient Dropoutdisease-modifying therapies; multiple sclerosis; outcome measurement; persistence to treatment; quality of lifeAdministration OralSelf AdministrationSex FactorKaplan-Meier EstimateRelapsing-Remittingmultiple sclerosisImmunologic Factor0302 clinical medicineQuality of lifeRetrospective StudieRisk FactorsMedicine030212 general & internal medicineDisease-modifying therapiedisease-modifying therapiesDisease-modifying therapies Multiple sclerosis Outcome measurement Persistence to treatment Quality of life Administration Oral Adult; Female Follow-Up Studies Humans Immunologic Factors Injections Kaplan-Meier EstimateMale Multiple Sclerosis Relapsing-Remitting Patient Dropouts Prognosis Proportional Hazards Models Retrospective Studies Risk Factors Self Administration Sex Factors Time FactorsHazard ratioPrognosisNeurologyTolerabilityAdministrationSettore MED/26 - NeurologiaFemaleoutcome measurementHumanOralAdultmedicine.medical_specialtyPatient DropoutsTime FactorPrognosiFollow-Up StudieInjections03 medical and health sciencesRoute of administrationMultiple Sclerosis Relapsing-RemittingSex FactorsInternal medicineHumansImmunologic FactorsMultiple sclerosiAdverse effectProportional Hazards ModelsRetrospective Studiesbusiness.industryProportional hazards modelRisk FactorRetrospective cohort studyDiscontinuationDisease-modifying therapies; Multiple sclerosis; Outcome measurement; Persistence to treatment; Quality of life; Administration Oral; Adult; Female; Follow-Up Studies; Humans; Immunologic Factors; Injections; Kaplan-Meier Estimate; Male; Multiple Sclerosis Relapsing-Remitting; Patient Dropouts; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Self Administration; Sex Factors; Time Factorsquality of lifeProportional Hazards Modelpersistence to treatmentNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up StudiesJournal of neurology
researchProduct

Modeling human osteosarcoma in mice through 3AB‐OS cancer stem cell xenografts

2012

Osteosarcoma is the second leading cause of cancer-related death for children and young adults. In this study, we have subcutaneously injected—with and without matrigel—athymic mice (Fox1nu/nu) with human osteosarcoma 3AB-OS pluripotent cancer stem cells (CSCs), which we previously isolated from human osteosarcoma MG63 cells. Engrafted 3AB-OS cells were highly tumorigenic and matrigel greatly accelerated both tumor engraftment and growth rate. 3AB-OS CSC xenografts lacked crucial regulators of beta-catenin levels (E-cadherin, APC, and GSK-3beta), and crucial factors to restrain proliferation, resulting therefore in a strong proliferation potential. During the first weeks of engraftment 3AB-…

MaleIntegrin beta ChainsXENOGRAFTNudeAnimals; Bone Neoplasms; Collagen; Drug Combinations; Focal Adhesion Kinase 1; Gene Expression Regulation Neoplastic; Humans; Injections Subcutaneous; Integrin beta Chains; Laminin; Male; Mice; Mice Nude; Neoplasm Transplantation; Neoplastic Stem Cells; Osteosarcoma; Pluripotent Stem Cells; Proteoglycans; Proto-Oncogene Proteins c-akt; Signal Transduction; Transplantation Heterologous; Tumor Markers Biological3AB-OS CSCSBiochemistryMiceInduced pluripotent stem cellTumor MarkersOsteosarcomaHeterologousSubcutaneousXIAPGene Expression Regulation NeoplasticDrug CombinationsANIMAL MODELSNeoplastic Stem CellsOsteosarcomaProteoglycansCollagenMATRIGELSignal TransductionPluripotent Stem CellsInjections SubcutaneousTransplantation HeterologousMice NudeBone NeoplasmsBiologyInjectionsCyclin D2Cancer stem cellBiomarkers TumormedicineAnimalsHumansMolecular BiologyProtein kinase BNeoplasticTransplantationMatrigelMesenchymal stem cellCell BiologyBiologicalmedicine.disease3AB-OS CSCS; OSTEOSARCOMA; XENOGRAFT; MATRIGEL; ANIMAL MODELSGene Expression RegulationFocal Adhesion Kinase 1ImmunologyCancer researchLamininProto-Oncogene Proteins c-aktNeoplasm TransplantationJournal of Cellular Biochemistry
researchProduct

Intravitreal aflibercept for the treatment of radiation-induced macular edema after ruthenium 106 plaque radiotherapy for choroidal melanoma.

2019

Purpose: To assess the efficacy of intravitreal aflibercept in patients suffering from post-radiation macular edema following plaque radiotherapy for choroidal melanoma. Methods: This prospective, interventional case series included patients affected by radiation maculopathy (RM) with macular edema secondary to ruthenium-106 plaque brachytherapy for choroidal melanoma. The effect of intravitreal aflibercept on best-corrected visual acuity (BCVA), central foveal thickness (CFT) detected by spectral domain optical coherence tomography (sd-OCT), and Horgan’s grading scale of RM was evaluated throughout the 24-month follow-up. Intraocular pressure (IOP) and possible complications were also reco…

MaleIntraocular pressureFovea CentralisVisual acuitygenetic structuresmedicine.medical_treatmentBrachytherapyVisual AcuityIntravitreal aflibercept; Plaque brachytherapy; Radiation maculopathy; Aged; Brachytherapy; Choroid Neoplasms; Dose-Response Relationship Drug; Dose-Response Relationship Radiation; Female; Fluorescein Angiography; Follow-Up Studies; Fovea Centralis; Fundus Oculi; Humans; Intravitreal Injections; Macular Edema; Male; Melanoma; Middle Aged; Prospective Studies; Receptors Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Ruthenium Radioisotopes; Tomography Optical Coherence; Treatment Outcome; Visual Acuity0302 clinical medicineEndophthalmitisReceptorsProspective StudiesFluorescein AngiographyTomographyMelanomaAfliberceptRadiationmedicine.diagnostic_testVascular Endothelial Growth FactorChoroid NeoplasmsMiddle AgedFluorescein angiographySensory SystemsTreatment OutcomeIntravitreal InjectionsFemaleIntravitreal aflibercept; Plaque brachytherapy; Radiation maculopathy; Aged; Brachytherapy; Choroid Neoplasms; Dose-Response Relationship; Drug; Dose-Response Relationship; Radiation; Female; Fluorescein Angiography; Follow-Up Studies; Fovea Centralis; Fundus Oculi; Humans; Intravitreal Injections; Macular Edema; Male; Melanoma; Middle Aged; Prospective Studies; Receptors; Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Ruthenium Radioisotopes; Tomography; Optical Coherence; Treatment Outcome; Visual Acuitymedicine.symptomIntravitreal afliberceptDrugRuthenium RadioisotopesTomography Optical CoherenceHumanmedicine.drugmedicine.medical_specialtyFundus OculiRecombinant Fusion ProteinsRuthenium RadioisotopeMacular EdemaFollow-Up StudieDose-Response Relationship03 medical and health sciencesCellular and Molecular NeuroscienceRadiation maculopathyOphthalmologymedicineHumansMacular edemaAgedFovea CentraliDose-Response Relationship Drugbusiness.industryPlaque radiotherapyIntravitreal InjectionPlaque brachytherapyDose-Response Relationship Radiationmedicine.diseaseeye diseasesProspective StudieOphthalmologyReceptors Vascular Endothelial Growth FactorOptical Coherence030221 ophthalmology & optometryMaculopathysense organsbusinessChoroid Neoplasm030217 neurology & neurosurgeryRecombinant Fusion ProteinFollow-Up StudiesGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
researchProduct

Hemin, an inducer of heme oxygenase-1, lowers intraocular pressure in rabbits.

2007

Carbon monoxide (CO) generated from heme may induce vasodilation and exert cyto-protective properties in the eye. This study was undertaken to investigate the effects of hemin, a potent inducer of heme oxygenase-1 (HO-1), on models of ocular hypertension in rabbits.Ocular hypertension was induced by injecting alpha-chymotrypsin in both eyes under local anesthesia. Only rabbits with an intraocular pressure (IOP) of 25 mmHg or more were used. The dose-response study of the hemin effect on IOP was made by an intravenous injection of the drug (50, 75, and 100 mg/kg) and subsequent IOP monitoring every 6 h. A separate set of animals was pretreated with the HO-1 inhibitor, zinc protoporphyrin-IX …

MaleIntraocular pressuregenetic structuresmedicine.drug_classOcular hypertensionProtoporphyrinsVasodilationPharmacologyBetamethasonechemistry.chemical_compoundRandom AllocationmedicineAnimalsChymotrypsinPharmacology (medical)Enzyme inducerIntraocular PressurePharmacologyAnalysis of VariancebiologyDose-Response Relationship Drugmedicine.diseaseeye diseasesHeme oxygenaseOphthalmologyDisease Models AnimalchemistryAnesthesiaEnzyme InductionInjections Intravenousbiology.proteinCorticosteroidBetamethasoneHeminOcular Hypertensionsense organsRabbitsHeme Oxygenase-1Heminmedicine.drugJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
researchProduct

l-[3H]lysine binding to rat retinal membrane: II. effect of kainic acid,d,l-?-aminoadipic acid, iodoacetic acid, and modification by dark-exposure

1986

The rat retina and the different brain regions contain membranes sites that bindl-lysine in the nanomolar range. These binding sites undergo changes in different experimental conditions, thus: I) intraocular injection of kainic acid induces a reduction of the density ofl-lysine binding sites, II)d,l-α-aminoadipic acid injected into the eye enhances both kinetic parameters (Bmax andKd) ofl-[3H]lysine binding sites, III) the intraperitoneal injection of iodoacetic acid decreases the sensitivity for its ligand binding sites, and IV) the exposure to darkness of the rats reducesl-[3H]lysine binding in the retina, thalamus, hypothalamus and superior colliculus, but not in the occipital cortex; su…

MaleKainic acidgenetic structuresIodoacetic acidmedicine.medical_treatmentIntraperitoneal injectionLysineIodoacetates2-Aminoadipic AcidBiologycomplex mixturesBiochemistryRetinaCellular and Molecular Neurosciencechemistry.chemical_compoundmedicineAnimalsVisual PathwaysBinding siteKainic AcidLysineBrainRetinalGeneral MedicineDarknessAmino Acids DicarboxylicIodoacetic AcidRatsKineticschemistryBiochemistryDarknessBiophysicsbacteriasense organs2-Aminoadipic AcidNeurochemical Research
researchProduct

Influence of intravenously administered lidocaine on cerebral blood flow in a baboon model standardized under controlled general anaesthesia using si…

1993

The baboon under general anaesthesia as a model to assess drug-induced cerebral blood flow changes (delta CBF) using single-photon emission tomography (SPET) offers great in vivo possibilities but has to comply with demands on control of anaesthesia-related influencing factors, such as PaCO2 changes. The model sought in this study and described here allows control of PaCO2, in the baboon under thiopentone anaesthesia by ventilation, and was evaluated for the functional dependence of delta CBF vs delta PaCO2, using SPET technetium-99m hexamethylpropylene amine oxime (HMPAO) and the split-dose method together with controlled ventilation. During the experiment the model was validated for norma…

MaleLidocaineRespiratory rateHemodynamicsAnesthesia GeneralModels BiologicalTechnetium Tc 99m Exametazimebiology.animalOximesmedicineAnimalsRadiology Nuclear Medicine and imagingTomography Emission-Computed Single-Photonbiologybusiness.industryLidocaineGeneral MedicineBlood flowOrganotechnetium CompoundsBlood pressureCerebral blood flowAnesthesiaCerebrovascular CirculationInjections IntravenousBreathingbusinessmedicine.drugBaboonPapioEuropean journal of nuclear medicine
researchProduct

IL-5 Enhances in Vitro and in Vivo Antigen-Specific IgA Production in MHC Genetically Determined Low IL-5 Responder Mice

1995

Lymphonode cells from BALB/k mice, but not from BALB/c mice, immunized with picryl chloride (PCl) produce IL-5 when stimulated with the specific antigen in vitro and this correlates with picryl-specific IgA levels in vivo, which are 6 to 10 times higher in BALB/k mice. B lymphocytes from BALB/k mice cultured with PCl-immune T cells from BALB/k produce in vivo anti-PCl-IgA, while B lymphocytes from BALB/c mice, cultured with T cells from BALB/c mice, fail to produce appreciable amounts of anti-PCl IgA, unless IL-5 is added to cultures. B lymphocytes from both strains of mice produce similar amounts of total IgA antibodies when stimulated in vitro with lipopolysaccharide. In vivo administrati…

MaleLipopolysaccharideImmunologyPicryl ChlorideMajor histocompatibility complexMajor Histocompatibility ComplexPicryl chlorideEpitopesMicechemistry.chemical_compoundAntigenIn vivoAnimalsInterleukin 5Cells CulturedMice Inbred BALB CbiologyMolecular biologyMice Mutant StrainsRecombinant ProteinsIn vitroImmunoglobulin Achemistrybiology.proteinInterleukin-5AntibodyInjections IntraperitonealCellular Immunology
researchProduct

A prospective, randomized, triple-blind comparison of articaine and bupivacaine for maxillary infiltrations

2011

Objectives: To compare the clinical anesthetic efficacy of 0.5% bupivacaine and 4% articaine (both with 1:200.000 adrenaline) for anterior maxillary infiltration in healthy volunteers. Material and methods: A triple-blind split-mouth randomized clinical trial was carried out in 20 volunteers. A supraperiosteal buccal injection of 0.9 ml of either solution at the apex of the lateral incisor was done in 2 appointments separated 2 weeks apart. The following outcome variables were measured: latency time, anesthetic efficacy (dental pulp, keratinized gingiva, alveolar mucosa and upper lip mucosa and tissue) and the duration of anesthetic effect. Hemodynamic parameters were monitored during the p…

MaleLocal anesthesiaAnestèsia en odontologiaTime FactorsLidocaineAnesthesia DentalDentistryJawsCarticaineArticaineInjectionsYoung AdultCarticainestomatognathic systemMaxillamedicineHumansProspective StudiesAnesthetics LocalGeneral DentistryAlveolar mucosaBupivacaineMaxil·larsbusiness.industryClinical and Experimental dentistryHemodynamicsLidocaineAnestèsia localBuccal administration:CIENCIAS MÉDICAS [UNESCO]AmidesInjeccionsstomatognathic diseasesOtorhinolaryngologyResearch DesignAnesthesiaMaxillaUNESCO::CIENCIAS MÉDICASAnestheticResearch-ArticleFemaleSurgeryAnesthesia in dentistrybusinessAnesthesia Localmedicine.drugMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

2013

International audience; BACKGROUND: The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety of oral rivaroxaban administered for an extended period, as compared with subcutaneous enoxaparin administered for a standard period, followed by placebo. METHODS: We randomly assigned patients 40 years of age or older who were hospitalized for an acute medical illness to receive subcutaneous enoxaparin, 40 mg once daily, for 10±4 days and oral placebo for 35±4 days or to receive subcutaneous placebo for 10±4 days and oral rivaroxaban, 10 mg onc…

MaleMESH: Factor Xa[SDV]Life Sciences [q-bio]Administration Oral030204 cardiovascular system & hematologylaw.inventionMESH: Venous Thromboembolismchemistry.chemical_compound0302 clinical medicineRivaroxabanRandomized controlled triallawMedicineMESH: Double-Blind Method030212 general & internal medicineMESH: AgedMESH: Middle AgedVenous ThromboembolismGeneral MedicineMiddle AgedMESH: Thiophenes3. Good healthAnesthesiaAcute DiseaseMESH: Administration OralMESH: Acute DiseaseFemaleMESH: Hemorrhagemedicine.drugAdultRandomizationMESH: EnoxaparinInjections SubcutaneousMorpholinesMESH: MorpholinesHemorrhageThiophenesMESH: AnticoagulantsMESH: Drug Administration SchedulePlaceboDrug Administration Schedule03 medical and health sciencesDouble-Blind MethodRivaroxaban venous thromboembolismHumansEnoxaparinAgedRivaroxabanMESH: Humansbusiness.industryMESH: Injections SubcutaneousAnticoagulantsMESH: AdultConfidence intervalMESH: MalechemistryBetrixabanRelative riskbusinessVenous thromboembolismMESH: FemaleFactor Xa Inhibitors
researchProduct

Antiaggressive and motor effects of haloperidol show different temporal patterns in the development of tolerance.

1993

Abstract The study of the temporal course of tolerance development was used as a means to separate different aspects of the action of haloperidol on social behavior. Agonistic behavior was studied in isolated male mice that confronted standard opponents (anosmic and grouped conspecifics) in a neutral area. The aggressive and motor behaviors of the experimental animals were evaluated 30 min or 24 h either after a single injection of haloperidol (0.4 mg/kg) or following the last of a series of 15 or 30 injections. When animals were evaluated 30 min after the haloperidol injection, no tolerance to the antiaggressive effects was evident. The action on immobility, on the contrary, showed a clear…

MaleMale miceExperimental and Cognitive PsychologyPharmacologyMotor ActivityDrug Administration ScheduleBehavioral NeuroscienceMiceNeural PathwaysAgonistic behaviourHaloperidolmedicineAnimalsDose-Response Relationship DrugDrug administrationBrainSingle injectionHaloperidol injectionBehavioral analysisAggressionHaloperidolPsychologyArousalNeuroscienceAgonistic Behaviormedicine.drugPhysiologybehavior
researchProduct